LifeStance Health Group, Inc. $LFST Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd decreased its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST) by 36.7% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 54,807 shares of the company’s stock after selling 31,839 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in LifeStance Health Group were worth $283,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of LFST. DekaBank Deutsche Girozentrale purchased a new position in LifeStance Health Group in the first quarter valued at $31,000. Park Edge Advisors LLC acquired a new stake in LifeStance Health Group in the 2nd quarter valued at about $52,000. Xponance Inc. acquired a new position in shares of LifeStance Health Group during the first quarter worth about $69,000. Public Employees Retirement System of Ohio acquired a new position in shares of LifeStance Health Group during the second quarter worth about $70,000. Finally, Blair William & Co. IL purchased a new stake in shares of LifeStance Health Group during the second quarter worth approximately $70,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Darren M. Black sold 8,407,643 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the sale, the director owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the transaction, the insider owned 33,524,715 shares in the company, valued at $169,970,305.05. This trade represents a 20.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 20,407,643 shares of company stock valued at $103,466,750. Insiders own 3.20% of the company’s stock.

LifeStance Health Group Stock Up 0.6%

Shares of NASDAQ LFST opened at $6.29 on Friday. The stock has a market cap of $2.45 billion, a PE ratio of -209.67 and a beta of 1.15. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.30. The business has a 50-day moving average price of $5.30 and a 200 day moving average price of $5.27. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.19.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. The business had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company’s revenue was up 16.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.02) earnings per share. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Analysts Set New Price Targets

LFST has been the topic of a number of analyst reports. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday. UBS Group lifted their price target on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday. BTIG Research upped their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen downgraded LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of LifeStance Health Group in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.